FDA Adverse Event Injury Summary report: N

ACCU-CHEK SPIRIT COMBO

MDR report key: 3052078 · Received April 11, 2013

Report

Report Number
2183996-2013-00640
Event Type
Injury
Date Received
April 11, 2013
Date of Event
March 27, 2013
Report Date
April 15, 2013
Manufacturer
ROCHE DIABETES CARE AG
Product Code
LZG
PMA / PMN Number
K111353
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IN, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

IT IS UNKNOWN IF THE INITIAL REPORTER SENT REPORT TO FDA. DEVICE WILL NOT BE RETURNED.

Additional Manufacturer Narrative · 1

AS THE PRODUCT HAS NOT BEEN RETURNED FOR INVESTIGATION AND THE PRODUCTION DATA COMPLY WITH THE SPECIFICATIONS, THE COMPLAINT COULD NOT BE REPLICATED. PRODUCTION REPORTS WERE REVIEWED. (B)(4): DEVICE WAS NOT RETURNED TO MANUFACTURER.

Description of Event or Problem · 1

ON (B)(6) 2013, A COMPANY REPRESENTATIVE REPORTED THAT THE PATIENT HAD EXPERIENCED BLOOD GLUCOSE PROBLEMS WITHIN THE FIRST 24 HOURS OF USING HIS NEW INFUSION DEVICE. BEFORE SWITCHING TO INFUSION DEVICE THERAPY, HIS BLOOD GLUCOSE LEVELS FLUCTUATED FROM 20-400'S MG/DL. DURING THAT FIRST 24 HOURS, AT 5:30PM ON (B)(6) 2013, HIS BLOOD GLUCOSE LEVEL DROPPED TO 29 MG/DL AND AFTER DRINKING JUICE IT RETURNED TO NORMAL. THE PATIENT REQUIRED OUTSIDE ASSISTANCE RETRIEVING THE JUICE AND WOULD NOT HAVE BEEN ABLE TO SELF-TREAT THE LOW BLOOD GLUCOSE LEVEL. THE PATIENT'S NURSE NOTICED THE PATIENT NEEDED ASSISTANCE DUE TO A "BLANK STARE". TROUBLESHOOTING WITH THE PATIENT DID NOT REVEAL ANY PROBLEMS WITH THE PERFORMANCE OF THE INFUSION DEVICE. ADDITIONAL TRAINING HAS BEEN OFFERED TO THE PATIENT; THE PATIENT HAS DISCONTINUED USE OF THE DEVICE UNTIL ADDITIONAL TRAINING IS RECEIVED. NO PRODUCT WILL BE REQUESTED TO BE RETURNED FOR EVALUATION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
156863 ACCU-CHEK SPIRIT COMBO INSULIN INFUSION PUMP LZG ROCHE DIABETES CARE AG NA NA

Patients

Seq Age Sex Outcome Treatment
1 055 YR Required Intervention NOVOLOG| LANTUS